



## A Review Zika Virus-Old Wine in a New Bottle

Mujahid Mohammed\* and Farah Ghani

Department of Animal Science, Hyderabad Central University, Hyderabad, Telangana

\*Corresponding author: Mujahid Mohammed, Department of Animal Science, Hyderabad Central University, Hyderabad, Telangana, E-mail: mujahid.1567@outlook.com

Received: March 02, 2017; Accepted: March 21, 2017; Published: March 26, 2017

### Abstract

Zika virus is a vector-borne flavivirus that serves a public health emergency is a still ongoing epidemic in the under developing countries, mostly Latin America. This uncertain virus was limited to sporadic cases in Africa and Asia until the emergence of Zika virus in Brazil in 2015 when it rapidly spread everywhere the Americas. Most of the Zika virus infections found to be subclinical or characterised by mild hot disease. However, neurological difficulties, including Guillain-Barré syndrome in adults, and congenital aberrations, including microcephaly in infants born to infected mothers, raised a serious concern. Currently, there is no specific antiviral medication or vaccine ready for Zika virus infection. Thus, global public health response is primarily focused on countering infection, alone in pregnant women, and on implementing up-to-date support to reduce the risk of non-vector transmission of Zika virus

*Keywords: Zikavirus; Host-parasite interaction*

### Introduction

ZIKV was identified in the year 1947 from a Rhesus monkey in the Zika Forest of Uganda Prior to 2007, seroprevalence studies in Asia and Africa suggested ZIKV infections occurred regularly without a sign of severe infection. Outbreaks of ZIKV arose in 2007 on Yap Island in the Federated States of Micronesia followed by an epidemic in French Polynesia in 2013. Historically, Zika virus (ZIKV) infection caused a mild, self-limiting febrile illness that was associated with conjunctivitis, rash, headache, myalgia, and arthralgia [1-6]. However, during the recent epidemics in Asia and the Americas, more severe and unusual clinical consequences have been observed. Infection of fetuses during pregnancy, particularly during the first trimester, has been associated with placental insufficiency and congenital malformations including cerebral calcifications, microcephaly, and miscarriage [2,3,4-6]. In adults, ZIKV ranks as the most frequent disease among women and men with age 0-28 years of age infection is linked to an increased incidence of Guillain- Barre´ syndrome (GBS), an autoimmune disease characterized by ascending paralysis and polyneuropathy [7-12] that occurs during the acute phase of ZIKV infection or shortly afterward [8–10]. We have seen in increase in the publication of research paper day by day exponentially and numerous open access journal came to existence to provide more information and precaution to overcome the diseases, literally to say nearly about 250 research paper published in one day from different geographical arena.

CDC has updated its guidance for world health organisation providers caring for women of reproductive age with possible Zika virus susceptibility to include guidance on counselling women and men with possible Zika virus susceptibility who is

interested in superfetation [13-18]. European-Society-of-Clinical-Microbiology-&-Infectious-Disease based in Switzerland founding in 1983, ESCMID has evolved to become Europe's leading society in clinical microbiology and infectious diseases with members of all European countries and complete continents around the globe. This guidance is based on limited accessible data on the constancy of Zika virus RNA in blood and semen. Women who have Zika virus infection should wait at least 8 weeks after symptom start to attempt apprehension, and men with Zika virus disease should wait at least 6 months after symptom onset to attempt conception. Saint-Petersburg-State-University comprises of the study of parasitic systems – which can be defined as a complex of species populations of the hosts united by the parasite population into a general supra-system in the parasite system for understanding the locally condition with temperature[19-25].

Zika virus can be spread from infected men and women through vaginal, oral or anal intercourse. Olger Calderon-Arguedas, is a professor in Parasitology University of Costa Rica with the research interest agents of vector borne disease, study of arthropod, study of the ecology of Rickettsia and present research interest on the zika. Zika virus RNA has been detected in blood, semen, cervical mucus and vaginal fluid. Currently, the CDC advises that infected men's need to wait up to six months, and infected women two months approx., prior to attempting pregnancy. Reproductive tissue donors should wait 6 months before giving a specimen [26-32]. Lalitha Gupta is working as Professor of Biological Sciences Laboratory of Molecular Parasitology and Vector Biology at Birla Institute of Technology & Science, India with research interest understanding the dengue and Plasmodium development [33-35].

### **Challenges behind the ZIKV vaccine**

This disease is attributed in part to ADE, whereby cross-reactive antibodies from the first DENV infection bind but fail to neutralize the second DENV serotype, and instead augment infection in myeloid cells expressing Gamma receptors [43]. This phenomenon could be relevant to ZIKV vaccination because DENV and ZIKV are related closely to one another, the two viruses co-circulate, and their infections produce cross-reactive antibodies targeting the highly conserved DII-FL epitope of the E protein. Indeed, studies in cell culture have confirmed that ADE can occur reciprocally, with DENV and ZIKV antibodies augmenting infection of ZIKV and DENV, respectively [30, 46-50]. Moreover, anti-ZIKV human monoclonal antibodies can enhance DENV infection and disease in mice [51-52] and reciprocally, anti-DENV and anti-WNV polyclonal antibodies enhanced ZIKV infection and disease in mice [53-57]. If ZIKV antibody responses are shown to augment DENV infection and disease in humans, vaccine strategies that minimize the generation of cross-reactive antibodies may be required to avoid sensitizing ZIKV vaccine recipients to severe DENV infections. In this case, soluble E protein or virus-like particle (prM-E) antigens that abrogate the DII-FL epitope but retain other protective epitopes may be useful [44,54,58-63]. (b) Guillain–Barre´ syndrome. Zika virus vaccine development Fernandez and Diamond. Currently, there is an epidemiological association between ZIKV infection and GBS, although a causal link has not yet been established. The pathogenesis of GBS might be due to direct ZIKV infection of neurons and glial cells in the spinal cord or to autoimmune-mediated targeting, possibly due to antibodies or T cells that cross react between viral and host antigens [10,64-69].

Beyond the generation of an immunogenic vaccine that elicits protective humoral and cell-mediated immunity, there are unique challenges to developing a ZIKV vaccine: (a) Immune enhancement of heterologous DENV infection [36-40]. The DENV complex is comprised of four genetically related serotypes. Olger Calderón-Arguedas publishes his review article with a title “*Zika Virus (ZIKA: New Emerging Pathogen Transmitted by Aedes Mosquitoes (Diptera: Culicidae) in the Latin American Subcontinent*” whereas primary infection with DENV generates a protective antibody response that protects durably against the homologous serotype, secondary infection with a heterologous DENV serotype can result in a severe

capillary permeability shock syndrome. *Entomological Impact and Current Perceptions of Novaluron and Temephos against the Aedes Aegypti (Skuse) Vector of Dengue, Chikungunya and Zika Arboviruses in a Coastal Town in Ecuador* deals with the were compared in a field trial in Colonche, Ecuador against *Aedes aegypti* (Skuse). Community perceptions of dengue fever along with acceptance of new methods were evaluated [41-45].

Prior to deployment of a ZIKV vaccine, it will be important to confirm that the elicited humoral or cellular anti-ZIKV responses in humans do not promote the development of GBS. (c) Pregnancy. Many vaccines are avoided during pregnancy due to the possible risks of infection or inflammation to the developing fetus. Indeed, vaccination prior to pregnancy remains the desired approach. Notwithstanding this, retrospective analysis of administered live-attenuated or inactivated vaccines has failed to establish conclusively adverse outcomes in fetuses of vaccinated mothers [70-75].

The current recommendation is to administer vaccines if the disease risk outweighs the potential of vaccine related effects [76-80]. Several recent studies suggest a relatively high frequency of adverse neurodevelopmental effects of fetuses of symptomatic and asymptomatic pregnant women following ZIKV infection [6, 81-84]. With current information, it remains difficult to determine whether the risk of exposure to ZIKV in utero surpasses that associated with immunization with certain classes of vaccines.

## Conclusion

While optimism remains high for generating protective vaccines against ZIKV across multiple platforms, questions remain about their safety because of the unique clinical manifestations of ZIKV and its genetic and serological relatedness to DENV. Parallel discovery and epidemiological efforts are needed to address these issues prior to widespread implementation of a ZIKV vaccine [85-90].

## REFERENCE

1. Paquet S, et al. Seroprevalence of Influenza A (H1N1) pdm09 Infection and Risk Factors Associated in Pikine, Dakar Region, Senegal. *J Emerg Infect Dis.* 2016;1:119.
2. Ndubuisi NO, et al. Delay in Diagnosis of Pulmonary Tuberculosis among Presumptive Tuberculosis Cases in Parts of Anambra State, Nigeria. *J Emerg Infect Dis.* 2016;1:120.
3. Yong TY, et al. Urinary Tract Infections in Older People with Long-Term Indwelling Catheters. *J Emerg Infect Dis.* 2016;1:e002.
4. Ben Ayed N, et al. The Re-Emergence of Whooping Cough in Sfax (Southern Tunisia). *J Emerg Infect Dis.* 2016;1:110.
5. Pizzol D, et al. Local Food Resources to Fight Children Malnutrition and Infectious Diseases in Mozambique. *J Emerg Infect Dis.* 2016;1:111.
6. Emhemid K, et al. Empyema Caused by Unusual Pathogen *Campylobacter*. *J Emerg Infect Dis.* 2016; 1:112.
7. Wan X, et al. Expression and Characterization of Capsid Proteins Derived from GII.17 and GII.7 Noroviruses. *J Emerg Infect Dis.* 2016;1:113.
8. Das A, et al. A One-Stop Novel Drug for Malaria Treatment and Control. *J Emerg Infect Dis.* 2016; 1:107.
9. Wangikar P, et al. Update on Methyltransferase Inhibitors of the Dengue Virus and Further Scope in the Field. *J Emerg Infect Dis.* 2016;1:108.
10. Wiwanitkit V. Emerging Infectious Disease during a War: Interesting Topic! *J Emerg Infect Dis.* 2016;1:e001.
11. Kashyap B, et al. Antigenic Screening for *Helicobacter pylori* in Stool of Patients Infected with Human Immunodeficiency Virus from a Tertiary Care Hospital. *J Emerg Infect Dis.* 2015;1:101.

12. Jena L, et al. Isoniazid with Multiple Mode of Action on Various Mycobacterial Enzymes Resulting in Drug Resistance. *J Infect Dis Ther.* 2016;4:297.
13. Anandan S, et al. Synergy Testing between Sulbactam and Meropenem/ Colistin in MDR *Acinetobacter baumannii-calcoaceticus* Complex Isolated from Ventilator Associated Pneumonia. *J Infect Dis Ther.* 2016;4:299.
14. Farrag HA, et al. Prevalence of pathogenic bacterial isolates infecting wounds and their antibiotic sensitivity. *J Infect Dis Ther.* 2016;4:1-7.
15. Hongling L, et al. Preliminary Research of Off-Line Bioartificial Liver on Patients with Hbv Related Acute-On-Chronic Liver Failure. *J Infect Dis Ther.* 2016;6:303.
16. Kaur I, et al. Analysis of Microbial Resistance and Prescription Preferences using Antibigrams. *J Infect Dis Ther.* 2016;4:302.
17. Ahmed SS, et al. Global Epidemiology on Colistin Resistant *Acinetobacter baumannii*. *J Infect Dis Ther.* 2016;4:287.
18. Khan S, et al. Prevalence of Substance Dependence among Susceptible TB Patients in a Private Sector Hospital in Karachi, Pakistan. *J Infect Dis Ther.* 2016;4:290.
19. Facchi DP, et al. N,N,N-Trimethyl Chitosan and Its Potential Bactericidal Activity: Current Aspects and Technological Applications. *J Infect Dis Ther.* 2016;4:291.
20. Kaur I. Novel Strategies to Combat Antimicrobial Resistance. *J Infect Dis Ther.* 2016;4:292.
21. Sharma A, et al. Mechanisms of Carbapenem Resistance in *K. pneumoniae* and *E. coli* from Bloodstream Infections in India. *J Infect Dis Ther.* 2016;4:293.
22. Giménez-García R, et al. Tularemia: A Case Report. *J Infect Dis Ther.* 2016; 4:282.
23. Ogawa Y, et al. Surgical Site Infection due To *Mycobacterium mageritense* and Literature Review. *J Infect Dis Ther.* 2016;4:283.
24. Miszewska-Szyszkowska D, et al. A Case of Rare Cutaneous Mycobacteriosis and Central Nervous System Post-Transplant Lymphoproliferative Disorder in a Female Patient after Kidney Transplantation. *J Infect Dis Ther.* 2016;4:285.
25. Bayasi G, et al. The Effect of Intravenous Vancomycin in the Reduction of the Incidence of *Clostridium difficile* Colitis. *J Infect Dis Ther.* 2016;4:286.
26. Zacarias JMV, et al. Letter to the Editor Concerning: “The Role of Human Leukocyte Antigen Typing in Libyan Patients with Chronic Periodontitis”. *J Infect Dis Ther.* 2016;4:279.
27. Breton-Martinez JR and Hernandez R. Primary Meningococcal-C Conjunctivitis in a Vaccinated Child. *J Infect Dis Ther.* 2016;4:261.
28. Zagala AF, et al. Adherence of Physicians-in-Training to the 2009 International Standards for Tuberculosis Care (ISTC) at the University of the Philippines-Philippine General Hospital. *J Infect Dis Ther.* 2016;4:265.
29. Rong-Yu Y, et al. Progress in Treatment and Prevention of Trichinellosis. *J Infect Dis Ther.* 2015;3:251.
30. Koren E, et al. Synergistic Aspects to Explain the Pathophysiology of Sepsis and Septic Shock-An Opinion. *J Infect Dis Ther.* 2015;3:254.
31. Ali AM, et al. *Helicobacter pylori* Infection and its Potential Role in Childhood Eczema. *J Immunol Tech Infect Dis.* 2016;5:1.
32. Fasciana T, et al. Rapid Identification by MALDI-TOF of *Neisseria elongata* Subspecies *nitroreducens* in an Endocarditis Case. *J Immunol Tech Infect Dis.* 2016;5:1.

33. Satchidanandam V, et al. Rv3881c from Mycobacterium tuberculosis Elicits Poly-Functional CD8+ T cells in PPD-Positive Healthy Volunteers and Affords Significant Protection in the Guinea Pig Model. *J Immunol Tech Infect Dis*. 2016;5:2.
34. Halwani MA, et al. Disseminated Cutaneous Herpes Zoster in an Immunocompetent Patient. *J Immunol Tech Infect Dis* 2016;5:4.
35. Matougui Nada, et al. Lipid-based nanoformulations of antimicrobial peptides to treat bacterial infectious diseases. *J Immunol Tech Infect Dis*. 2015;4:2.
36. Angelique Montagu. Evaluation of interaction mechanisms between Acinetobacter baumannii bacteria and lipidic nanocapsules by flow cytometry. *J Immunol Tech Infect Dis*. 2015;4:2.
37. Osazuwa F, et al. Markers of Inflammation among Nigerian Periodontitis Patients. *J Immunol Tech Infect Dis*. 2014;3:2.
38. Kashyap B, et al. Antigenic Screening for Helicobacter pylori in Stool of Patients Infected with Human Immunodeficiency Virus from a Tertiary Care Hospital. *J Emerg Infect Dis*. 2015;1:101.
39. Basso C, et al. Epidemiologically Relevant Container Types, Indices of Abundance and Risk Conditions for Aedes aegypti in Salto (Uruguay), a City under Threat of Dengue Disease. *J Emerg Infect Dis*. 2015;1:103.
40. Yong TY, et al. A Case Report of Acute Lobar Nephronia Caused by Enterobacter cloacae. *J Emerg Infect Dis*. 2016;1:104.
41. Wambani JR, et al. Global Situation and Trends of HIV, Influenza and Marburg Viruses: An Epidemiological Perspective. *J Emerg Infect Dis*. 2016;1:105.
42. Selmi N, et al. Was Guinea the Source of the Ebola Virus contagion? Evidence via a Dynamic Equicorrelation Model. *J Emerg Infect Dis*. 2016;1:106.
43. Nyaki FS, et al. Predictors of Nutritional Status in Patients Treated for Multidrug- Resistant Tuberculosis at a Referral Hospital in Tanzania. *J Clin Infect Dis Pract*. 2015;1:115.
44. Ongor H, et al. Prevalence of Rota-and Reoviruses in Turkey Enteritis in Turkey. *J Clin Infect Dis Pract*. 2016; 1:114.
45. Mandal A, et al. Disseminated BCG Disease in an Infant with Severe Combined Immunodeficiency. *J Clin Infect Dis Pract*. 2016;1:112.
46. Dalhoff A, et al. The Impact of Protein Binding on Antibacterial Activities of Antibiotics is more than Predicted by considering its Numerical Value Alone: Impact of Preparative and Incubation Methods on Different Pharmacodynamic Endpoints of  $\beta$ - Lactams, Macrolides, or Fluoroquinolones against Gram-positive and Gram-negative Bacteria-Part I. *J Clin Infect Dis Pract*. 2016;1:110.
47. Tessarolo F, et al. ATP Measurement in the Last Rinse Water of Automated Washer-Disinfectors: The Added Value of Every Load Monitoring. *J Clin Infect Dis Pract*. 2016;1:109.
48. Mogtomo MLK, et al. High Risk of Transfusion-Transmitted Malaria (TTM) from Student Blood Donors Living in the Town of Douala, Cameroon. *J Clin Infect Dis Pract*. 2016;1:108.
49. Al-Musa Z, et al. Risk Factors Associated with Clostridium difficile Infection in A Pediatric Hematology-Oncology Ward with Analysis of the Infection Control Measures. *J Clin Infect Dis Pract*. 2016;1:106.
50. Oghenevo O, et al. Antibiotic Resistance in Extended Spectrum Beta-Lactamases (Esbls) Salmonella Species Isolated from Patients with Diarrhoea in Calabar, Nigeria. *J Clin Infect Dis Pract*. 2016;1:107.
51. Sarkar S, et al. Killer Cell Immunoglobulin like Receptors (KIR) Gene Variations in Rheumatic Fever and Rheumatic Heart Disease Patients from North India. *J Clin Infect Dis Pract*. 2016;1:105.

52. Mabhala M, et al. The Perspective of Socioeconomic Inequalities and Infectious Disease in 21st Century. *J Clin Infect Dis Pract* 2016;1:103.
53. León-Ramírez LF, et al. Diagnosis of Spondylodiscitis with 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan in a Patient with Bacteremia. *J Clin Infect Dis Pract.* 2016;1:104.
54. Ozkaya D, et al. Evaluation of Patients with Hepatitis Delta Virus Infection at First Admission in Izmir, Turkey. *Jrl of Clin Inf Disea & Practices.* 2016;1:101.
55. Bansal A, et al. Chemical Genetics to Study Plasmodium Kinases. *J Clin Inf Disea & Practices.*2016;1:102.
56. Mogtomo MLK, et al. High Risk of Transfusion-Transmitted Malaria (TTM) from Student Blood Donors Living in the Town of Douala, Cameroon. *J Clin Infect Dis Pract.* 2016;1:108.
57. Al-Musa Z, et al. Risk Factors Associated with Clostridium difficile Infection in A Pediatric Hematology-Oncology Ward with Analysis of the Infection Control Measures. *J Clin Infect Dis Pract.*2016;1:106.
58. Oghenevo O, et al. Antibiotic Resistance in Extended Spectrum Beta-Lactamases (Esbls) Salmonella Species Isolated from Patients with Diarrhoea in Calabar, Nigeria. *J Clin Infect Dis Pract.* 2016;1:107.
59. Sarkar S, et al. Killer Cell Immunoglobulin like Receptors (KIR) Gene Variations in Rheumatic Fever and Rheumatic Heart Disease Patients from North India. *J Clin Infect Dis Pract.* 2016;1:105.
60. Mabhala M, et al. The Perspective of Socioeconomic Inequalities and Infectious Disease in 21st Century. *J Clin Infect Dis Pract.* 2016;1:103.
61. León-Ramírez LF, et al. Diagnosis of Spondylodiscitis with 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan in a Patient with Bacteremia. *J Clin Infect Dis Pra.* 250(4978):297-298.
62. Ongor H, et al. Prevalence of Rota-and Reoviruses in Turkey Enteritis in Turkey. *J Clin Infect Dis Pract.* 2016;1:114.
63. Jones B, et al. The Role of the Innate and Adaptive Immunity in Exercise Induced Muscle Damage and Repair. *J Clin Cell Immunol.* 2017;8:482.
64. Akhmatova N and Akhmatova E. Influence of MNRI on the Immune Status of Children with Down Syndrome. *J Clin Cell Immunol.* 2017;8: 483.
65. Sun D, et al. Candidemia with Prosthetic Aortic Graft: Case Report. *J Clin Cell Immunol.* 2017;8:484.
66. Peppicelli S, et al. Acidity of Microenvironment as a Further Driver of Tumor Metabolic Reprogramming. *J Clin Cell Immunol.* 2017;8:485.
67. Lerner A, et al. Comparison of the Reliability of 17 Celiac Disease Associated Bio-Markers to Reflect Intestinal Damage. *J Clin Cell Immunol.* 2017;8:486.
68. Landlinger C, et al. Combinatorial Vaccine against Complement Factor C5a and Amyloid Beta: A New Therapeutic Approach in Alzheimer's disease. *J Clin Cell Immunol.* 2017;8:487.
69. Mondal S, et al. Glyceryl Tribenzoate: A Flavoring Ingredient, Inhibits the Adoptive Transfer of Experimental Allergic Encephalomyelitis via TGF- $\beta$ : Implications for Multiple Sclerosis Therapy. *J Clin Cell Immunol.* 2017;8:488.
70. Liddell JR. Interplay between Nrf2 and NF- $\kappa$ B in Neuroinflammatory Diseases. *J Clin Cell Immunol.* 2017;8:489.
71. Chul P, et al. Overview of Clostridium difficile Infection in Cancer Patients. *J Infect Dis Diagn.* 2016;1:109.
72. Xu D, et al. Unique Epidemiological Patterns and Origin of the Outbreak of Human Infection with H7N9 AIV in China from 2013 to 2015. *J Infect Dis Diagn.* 2016;1:110.
73. Ali SA, et al. Role of Cultural and Social Barriers in Increased Burden of Hepatitis B in Pakistan: Literature Review. *J Infect Dis Diagn.* 2016;1:105.

74. Suhail N, et al. How to Prevent Hepatitis B in Pakistan: Role of Social Marketing. *J Infect Dis Diagn.* 2016; 1:106.
75. Fu Y, et al. A Summary of Acupuncture and Moxibustion Therapy for the Urinary Tract Infection after Stroke. *J Infect Dis Diagn.* 2016;1:107.
76. Kihara JH. Female Genital Schistosomiasis: A Neglected Tropical Disease Infecting Women of Reproductive Age in Endemic Areas. *J Infect Dis Diagn.* 2015;1:e101.
77. Iannuccelli V, et al. Inhaled Micro- or Nanoparticles: Which are the Best for Intramacrophagic Antiinfectious Therapies? *J Infect Dis Diagn.* 2015;1:e102.
78. Masgala A, et al. Multi Drug Resistant Gram Negative Pathogens in Long Term Care Facilities: A Steadily Arising Problem. *J Infect Dis Diagn.* 2015;1:101.
79. Wambani RJ, et al. Hepatitis B and C Co-Infections among HIV-1 Infected Patients Attending the Academic Model Providing Access to Healthcare Clinic, Kenya, 2014. *J Infect Dis Diagn.* 2015;1:102.
80. Wambani RJ, et al. Ebola Virus Disease: A Biological and Epidemiological Perspective of a Virulent Virus. *J Infect Dis Diagn.* 2016;1:103.
81. Tafreshi SH. Vaccination Age Changing from Infancy and Childhood to Adolescence and Adulthood: An In-Dispensable Approach in Immunization Programs. *J Infect Dis Ther.* 2016;4:304.
82. Rajadurai N. Tuberculous Tenosynovitis of the Wrist Joint: Imaging Findings on MRI. *J Infect Dis Ther.* 2016;4:307.
83. Fatnassi R, et al. Specificity of Brucellosis in Pregnancy: Presentation of Two Cases and Review of Literature. *J Infect Dis Ther.* 2016;4:308.
84. Tillotson G. The Fight against Bacterial Resistance - New Initiatives but Much Still Needed. *J Infect Dis Ther.* 2016;4:e109.
85. Abdelmalek SMA, et al. Impact of Dermatologists' Perceptions about Antibiotic Resistance on Antibiotic Prescribing for Acne. *J Infect Dis Ther.* 2016;4:294.
86. Erdem H, et al. Other Foci of Infections in Community Acquired Central Nervous System Infections. *J Meningitis* 2016;1:108.
87. Edwards TS, et al. The Orthopaedic Consequences of Childhood Meningococcal Septicaemia. *J Meningitis.* 2016;1:109.
88. Abbas A, et al. Visual Impairment in HIV Negative Tuberculosis Meningitis. *J Meningitis.* 2016;1:107.
89. Dharmarajan L, et al. Gender Differences in Community-acquired Meningitis in Adults: Clinical Presentations and Prognostic Factors. *J Meningitis.* 2016;1:106.
90. Babi MA, et al. A First Clinical Case Report of West-Nile Viral Meningoencephalitis Complicated with Acute Pancreatitis in North America. *J Meningitis.* 2016;1:104.